Crinetics Pharmaceuticals, Inc.CRNXNASDAQ
Loading
EV to Sales: Discounted ValuationCompressed
Percentile Rank67
3Y CAGR+42.4%
5Y CAGR-34.9%
Year-over-Year Change
Enterprise value to sales ratio
3Y CAGR
+42.4%/yr
vs +10.3%/yr prior
5Y CAGR
-34.9%/yr
Recent acceleration
Acceleration
+32.1pp
Accelerating
Percentile
P67
Within normal range
vs 5Y Ago
0.1x
Contraction
Streak
1 yr
Consecutive declineCompressed
| Period | Value | YoY Change |
|---|---|---|
| 2025 | 562.03 | -85.1% |
| 2024 | 3770.56 | +633.5% |
| 2023 | 514.08 | +164.2% |
| 2022 | 194.57 | -76.5% |
| 2021 | 829.63 | -82.7% |
| 2020 | 4796.45 | +900.7% |
| 2019 | 479.29 | +264.6% |
| 2018 | 131.45 | -17.5% |
| 2017 | 159.39 | -71.4% |
| 2016 | 557.24 | - |